Investor relations
Financial calendar
Zinzino Interim report Q3 2025
Zinzino Delårsrapport Q3 2025
Year-End Report 2025
Bokslutskommuniké 2025
Zinzino Interim report Q1 2026
Zinzino Delårsrapport Q1 2026
Financial reports
Press releases
ZINZINO AB (PUBL.): ZINZINO ACQUIRES TRUVY TO INCREASE DISTRIBUTION CAPACITY IN NORTH AMERICA, LATIN AMERICA, AND SOUTH KOREA
2025. szeptember 25. 9:00
MegnyitásZINZINO AB (PUBL.): ZINZINO ACQUIRES BODĒ PRO TO INCREASE DISTRIBUTION POWER IN NORTH AMERICA AND JAPAN
2025. szeptember 12. 16:30
MegnyitásZINZINO AB (PUBL.): LETTER OF INTENT TO ACQUIRE TRUVY FOR INCREASED DISTRIBUTION POWER IN NORTH AMERICA, LATIN AMERICA, AND SOUTH KOREA
2025. szeptember 05. 14:00
MegnyitásZINZINO AB (PUBL.): New study unveils global snapshot on Omega-3 deficiency – and why high-precision testing plus an enhanced formula can close the gap
2025. augusztus 18. 15:51
MegnyitásZINZINO AB (PUBL.): ZINZINO INITIATES NEGOTIATIONS FOR PART OWNERSHIP IN ANDORRA-BASED XION INTERNATIONAL GROUP FOR FURTHER DEVELOPMENT OF PROPRIETARY OMEGA-3 OIL AND SPIRULINA
2025. július 14. 14:00
MegnyitásZINZINO AB (PUBL.): Zinzino announces Philippines as next step in its global expansion
2025. június 12. 13:30
MegnyitásZINZINO AB (PUBL.): Zinzino acquires assets from Ecosystem for increased distribution power in France and DOM-TOM
2025. június 10. 13:30
MegnyitásZINZINO AB (PUBL.): Zinzino announces China as the next step in its global expansion
2025. május 16. 8:00
MegnyitásZINZINO AB (PUBL.): NOTICE TO THE ANNUAL GENERAL MEETING OF ZINZINO AB ON 28 MAY 2025
2025. április 28. 17:00
MegnyitásZINZINO AB (PUBL.): Zinzino acquires Valentus Global to increase distribution power in Europe
2025. április 11. 16:00
MegnyitásZINZINO AB (PUBL.): Zinzino announces New Zealand as next step in its global expansion
2025. március 11. 13:26
MegnyitásZINZINO AB (PUBL.): ANNOUNCES ACQUISITION OF ZURVITA’S ASSETS FOLLOWING SUCCESSFUL CHAPTER 11 PROCESS
2025. február 14. 8:00
MegnyitásZINZINO AB (PUBL.): ENTERS INTO AGREEMENT TO PROVIDE DIP FINANCING TO ZURVITA INITIATING CHAPTER 11 PROCESS
2024. december 21. 20:00
MegnyitásZINZINO AB (PUBL): Zinzino announces Canary Islands as next step in its global expansion
2024. november 13. 15:00
MegnyitásZINZINO AB (PUBL): Share subscription due to directed set-off issues
2024. szeptember 19. 15:30
MegnyitásZINZINO AB (PUBL.): ZINZINO ACQUIRES 49% OF CYPRIOT OLIVE OIL PRODUCER CLEANTHI ALPHA-OLENIC LTD
2024. június 27. 11:00
MegnyitásZINZINO AB (PUBL): LETTER OF INTENT TO ACQUIRE ZURVITA INCREASES DISTRIBUTION POWER IN NORTH AMERICA
2024. június 17. 11:00
MegnyitásZINZINO AB (PUBL): Zinzino announces Serbia as next step in its global expansion
2024. június 11. 15:30
MegnyitásZINZINO AB (PUBL): Zinzino now seeks acquisitions in the US and Asia to increase distribution power
2024. június 07. 12:00
MegnyitásZINZINO AB (PUBL): Zinzino acquires assets in Xelliss – strategic reinforcement in southern Europe and in the microalgae spirulina
2024. május 12. 13:00
MegnyitásZINZINO AB (PUBL): NOTICE OF ANNUAL GENERAL MEETING IN ZINZINO AB ON MAY 27, 2024
2024. április 26. 8:00
MegnyitásZINZINO AB (PUBL): Zinzino and ACN, enter a strategic partnership in Europe, and in connection with it Zinzino carries out a directed new issue of B shares for SEK 10.4 million.
2024. január 29. 10:00
MegnyitásZINZINO AB (PUBL): Zinzino changes Certified Adviser to Carnegie Investment Bank AB (publ)
2023. november 30. 9:00
MegnyitásZINZINO AB (PUBL): Zinzino announces Mexico as next step in its global expansion
2023. szeptember 22. 8:00
MegnyitásZINZINO AB (PUBL.): NOTICE TO THE ANNUAL MEETING OF ZINZINO AB ON MAY 31, 2023
2023. május 02. 8:00
MegnyitásZINZINO AB (PUBL): Zinzino launches Turkey as a next market on their road towards global expansion
2023. március 07. 14:30
MegnyitásGrowing interest in personal health and customized supplements can be a great investment case
2022. november 28. 14:30
MegnyitásZinzino announces the launch of Singapore as next step in their global expansion
2022. április 07. 11:30
MegnyitásZINZINO AB (PUBL): Zinzino acquires brand portfolio with Swiss skincare and supplements
2022. április 06. 9:30
MegnyitásZINZINO AB (PUBL): MEMBERS OF THE NOMINATION COMMITTEE FOR ZINZINO AB'S ANNUAL GENERAL MEETING IN 2022
2021. november 18. 14:00
MegnyitásZINZINO AB (PUBL): Zinzino announces the launch of South Africa as next step in their global expansion
2021. november 09. 11:30
MegnyitásZINZINO AB (PUBL): Zinzino announces launch of Taiwan as next step in the global expansion
2021. szeptember 09. 13:00
MegnyitásZINZINO AB (PUBL): Zinzino announces the launch of Malaysia as next step in their global expansion
2021. június 03. 11:00
MegnyitásZINZINO AB (PUBL): A new signature BalanceOil from the pioneers of test-based nutrition
2021. április 15. 15:00
MegnyitásZINZINO AB (PUBL): Zinzino announces the launch of India as next step in their global expansion strategy
2021. április 06. 14:00
MegnyitásZINZINO AB (PUBL): Further expansions of the Zinzino global web shop
2020. december 15. 16:15
MegnyitásZINZINO AB (PUBL): ZINZINO MOVES TO THE PREMIER SEGMENT OF FIRST NORTH GROWTH MARKET
2020. szeptember 16. 10:00
MegnyitásZINZINO AB (PUBL): ONE-TIME EFFECT DUE TO CHANGED ACCOUNTING FOR DISTRIBUTOR REMUNERATION IMPROVES Q1 2020 WITH SEK 22.2 MILLION BEFORE TAX
2020. május 05. 12:00
MegnyitásZINZINO AB (PUBL): Zinzino and Life Leadership collaborate to provide test-based nutrition to expanding markets
2019. október 25. 16:40
MegnyitásZINZINO AB (PUBL.) APPOINTED “GROWTH COMPANY OF THE YEAR 2017” BY DIRECT SELLING SWEDEN
2018. június 01. 11:00
MegnyitásZINZINO AB (PUBL): Q1; CONTINUED SOUND GROWTH AND STRONG PROFITABILITY IMPROVEMENT, EBITDA RISING BY 45%
2018. május 15. 8:00
MegnyitásZINZINO AB (PUBL): STRONG GROWTH AND PROPOSAL FOR GREATLY INCREASED DIVIDENDS
2018. február 28. 8:00
MegnyitásZINZINO AB (PUBL): PRELIMINARY SALES REPORT FOR Q4 AND 2017 WITH PROPOSAL TO INCREASE DIVIDEND
2018. január 19. 18:00
MegnyitásInterim report, July – September 2017: IMPROVED GROSS MARGINS AND STRONG GROWTH IN THE DOMESTIC MARKET.
2017. november 13. 8:30
MegnyitásZinzino launches groundbreaking product: BalanceOil Vegan for the heart and brain
2017. október 20. 13:00
MegnyitásZINZINO AB (PUBL): CORRECTION: PRELIMINARY SALES REPORT THIRD QUARTER 2017
2017. október 10. 17:00
MegnyitásInterim Report, Zinzino, April – June 2017: Very strong growth of 28% and full-scale launch of a new digital platform
2017. augusztus 31. 9:00
MegnyitásZINZINO LAUNCHES VIVA, A NEW DIETARY SUPPLEMENT PROMOTING BETTER SLEEP, REDUCING STRESS AND INCREASING WELL-BEING
2017. június 30. 15:00
MegnyitásZinzino AB (publ.) appointed “Growth Company of the Year 2016” in direct sales
2017. június 02. 16:00
MegnyitásZinzino begins selling in Switzerland ”Rich in capital and an important market”
2017. május 16. 16:00
MegnyitásInterim Report, January – March 2017: Zinzino continues to deliver strong growth and is well prepared for increased profitability
2017. május 10. 9:00
MegnyitásZinzino taking the Omega-6/Omega-3 concept to new heights with water-miscible AquaX oil
2016. július 07. 16:24
MegnyitásSweden's Zinzino is improving its foothold in Europe – with the establishment of operations in Germany
2016. február 22. 8:00
MegnyitásZinzino launches Zinzino LeanShake – a nutritious meal replacement for weight control
2015. december 11. 11:58
MegnyitásSwedish Zinzino continues to grow internationally with its establishment in Canada
2015. szeptember 17. 9:28
MegnyitásZinzino AB (publ) acquires further 13.8 per cent of Faun Pharma AS – safeguarding continued research and expanded product range
2015. március 06. 10:29
MegnyitásFinancial Statements 1 January - 31 December 2014, Zinzino AB (publ)
2015. február 27. 14:39
MegnyitásThe stock
Zinzino Interim Report Q2 2025 – Interview
Carlsquare interviews CEO Dag Bergheim Pettersen about Zinzino’s Interim Report for Q2 2025.
Sustainability Report
Read more about our sustainability approach, targets and 2023 performance.
Elizabeta Sekulovska
shares@zinzino.com
+46 (0)763 066 954
Fredrik Nielsen
shares@zinzino.com
+46 (0)707 900 174
Certified Adviser
All companies whose shares are to be traded on the Nasdaq First North Premier Growth Market have a certified adviser who guides and supports the company through the listing process. Subsequently, the adviser monitors that the company complies with First North's regulations for providing information to the market and investors. DNB Carnegie Investment Bank AB (publ) is the Certified Adviser for Zinzino AB.
Certified Adviser:
The Company’s Certified Adviser is DNB Carnegie Investment Bank AB (publ)
Phone: +46 (0)738 564 265
E-mail: certifiedadviser@carnegie.se
Why invest in Zinzino
Strong market position and distribution
Zinzino has strong sales organisations in its principal markets with good relationships with its customer base. The broad product portfolio attracts new customer groups and thereby generates growth. Through an updated IT platform and logistics system, Zinzino is well equipped for the expected sales growth in the coming years.
Attractive cash flow enables increased stock dividends and gives a good direct return
Zinzino’s business has a very strong cash-generating capability. Effective management of working capital combined with investments that quickly generate revenue and marginal improvements generate a strong cash flow. Thus, dividends can be distributed in accordance with the target of at least 50 per cent of the free cash flow.
A clear global strategy with a growth-driven, future-proof business model
Zinzino is one of Europe’s fastest-growing direct sales companies with an aggressive global expansion strategy. The Scandinavian-based health tech company is currently operating in Europe, North America, Asia, Australia, India and Africa. The overall company strategy and business model is to achieve profitable growth in new as well as existing markets. The massive growth momentum of the past decade is expected to stay constant thanks to the stability and structure of the business model in combination with top-of-the-line digital market tools as well as continuous company acquisitions.
Help improve the health of the world
Our product concept is to give health back to the world. Our goal is to get the best out of people with enthusiasm, encouragement and a great deal of energy. We are the most customer-focused direct sales company in the world. Our most important product concept, Balance, is showing continued good growth and we currently have over 500,000 test results based on blood tests in our database. We are the company that has done the most fatty acid analyses in the world.
Product development at the leading edge
Through efficient product development in-house, the company has developed a number of new products in health in which it owns its own important intellectual property rights. The newly developed products are manufactured in our own efficient production facility which means that we have 100% quality control. Zinzino’s strategy in the coming years includes continued product development at the leading edge.
Attractive cash flow enables increased stock dividends and gives a good direct return
Zinzino’s business has a very strong cash-generating capability. Effective management of working capital combined with investments that quickly generate revenue and marginal improvements generate a strong cash flow. Thus, dividends can be distributed in accordance with the target of at least 50 per cent of the free cash flow.
A clear global strategy with a growth-driven, future-proof business model
Zinzino is one of Europe’s fastest-growing direct sales companies with an aggressive global expansion strategy. The Scandinavian-based health tech company is currently operating in Europe, North America, Asia, Australia, India and Africa. The overall company strategy and business model is to achieve profitable growth in new as well as existing markets. The massive growth momentum of the past decade is expected to stay constant thanks to the stability and structure of the business model in combination with top-of-the-line digital market tools as well as continuous company acquisitions.
Help improve the health of the world
Our product concept is to give health back to the world. Our goal is to get the best out of people with enthusiasm, encouragement and a great deal of energy. We are the most customer-focused direct sales company in the world. Our most important product concept, Balance, is showing continued good growth and we currently have over 500,000 test results based on blood tests in our database. We are the company that has done the most fatty acid analyses in the world.
Product development at the leading edge
Through efficient product development in-house, the company has developed a number of new products in health in which it owns its own important intellectual property rights. The newly developed products are manufactured in our own efficient production facility which means that we have 100% quality control. Zinzino’s strategy in the coming years includes continued product development at the leading edge.
Strong market position and distribution
Zinzino has strong sales organisations in its principal markets with good relationships with its customer base. The broad product portfolio attracts new customer groups and thereby generates growth. Through an updated IT platform and logistics system, Zinzino is well equipped for the expected sales growth in the coming years.
A clear global strategy with a growth-driven, future-proof business model
Zinzino is one of Europe’s fastest-growing direct sales companies with an aggressive global expansion strategy. The Scandinavian-based health tech company is currently operating in Europe, North America, Asia, Australia, India and Africa. The overall company strategy and business model is to achieve profitable growth in new as well as existing markets. The massive growth momentum of the past decade is expected to stay constant thanks to the stability and structure of the business model in combination with top-of-the-line digital market tools as well as continuous company acquisitions.
Help improve the health of the world
Our product concept is to give health back to the world. Our goal is to get the best out of people with enthusiasm, encouragement and a great deal of energy. We are the most customer-focused direct sales company in the world. Our most important product concept, Balance, is showing continued good growth and we currently have over 500,000 test results based on blood tests in our database. We are the company that has done the most fatty acid analyses in the world.
Product development at the leading edge
Through efficient product development in-house, the company has developed a number of new products in health in which it owns its own important intellectual property rights. The newly developed products are manufactured in our own efficient production facility which means that we have 100% quality control. Zinzino’s strategy in the coming years includes continued product development at the leading edge.
Strong market position and distribution
Zinzino has strong sales organisations in its principal markets with good relationships with its customer base. The broad product portfolio attracts new customer groups and thereby generates growth. Through an updated IT platform and logistics system, Zinzino is well equipped for the expected sales growth in the coming years.
Attractive cash flow enables increased stock dividends and gives a good direct return
Zinzino’s business has a very strong cash-generating capability. Effective management of working capital combined with investments that quickly generate revenue and marginal improvements generate a strong cash flow. Thus, dividends can be distributed in accordance with the target of at least 50 per cent of the free cash flow.
Help improve the health of the world
Our product concept is to give health back to the world. Our goal is to get the best out of people with enthusiasm, encouragement and a great deal of energy. We are the most customer-focused direct sales company in the world. Our most important product concept, Balance, is showing continued good growth and we currently have over 500,000 test results based on blood tests in our database. We are the company that has done the most fatty acid analyses in the world.
Product development at the leading edge
Through efficient product development in-house, the company has developed a number of new products in health in which it owns its own important intellectual property rights. The newly developed products are manufactured in our own efficient production facility which means that we have 100% quality control. Zinzino’s strategy in the coming years includes continued product development at the leading edge.
Strong market position and distribution
Zinzino has strong sales organisations in its principal markets with good relationships with its customer base. The broad product portfolio attracts new customer groups and thereby generates growth. Through an updated IT platform and logistics system, Zinzino is well equipped for the expected sales growth in the coming years.
Attractive cash flow enables increased stock dividends and gives a good direct return
Zinzino’s business has a very strong cash-generating capability. Effective management of working capital combined with investments that quickly generate revenue and marginal improvements generate a strong cash flow. Thus, dividends can be distributed in accordance with the target of at least 50 per cent of the free cash flow.
A clear global strategy with a growth-driven, future-proof business model
Zinzino is one of Europe’s fastest-growing direct sales companies with an aggressive global expansion strategy. The Scandinavian-based health tech company is currently operating in Europe, North America, Asia, Australia, India and Africa. The overall company strategy and business model is to achieve profitable growth in new as well as existing markets. The massive growth momentum of the past decade is expected to stay constant thanks to the stability and structure of the business model in combination with top-of-the-line digital market tools as well as continuous company acquisitions.
Product development at the leading edge
Through efficient product development in-house, the company has developed a number of new products in health in which it owns its own important intellectual property rights. The newly developed products are manufactured in our own efficient production facility which means that we have 100% quality control. Zinzino’s strategy in the coming years includes continued product development at the leading edge.
Strong market position and distribution
Zinzino has strong sales organisations in its principal markets with good relationships with its customer base. The broad product portfolio attracts new customer groups and thereby generates growth. Through an updated IT platform and logistics system, Zinzino is well equipped for the expected sales growth in the coming years.
Attractive cash flow enables increased stock dividends and gives a good direct return
Zinzino’s business has a very strong cash-generating capability. Effective management of working capital combined with investments that quickly generate revenue and marginal improvements generate a strong cash flow. Thus, dividends can be distributed in accordance with the target of at least 50 per cent of the free cash flow.
A clear global strategy with a growth-driven, future-proof business model
Zinzino is one of Europe’s fastest-growing direct sales companies with an aggressive global expansion strategy. The Scandinavian-based health tech company is currently operating in Europe, North America, Asia, Australia, India and Africa. The overall company strategy and business model is to achieve profitable growth in new as well as existing markets. The massive growth momentum of the past decade is expected to stay constant thanks to the stability and structure of the business model in combination with top-of-the-line digital market tools as well as continuous company acquisitions.
Help improve the health of the world
Our product concept is to give health back to the world. Our goal is to get the best out of people with enthusiasm, encouragement and a great deal of energy. We are the most customer-focused direct sales company in the world. Our most important product concept, Balance, is showing continued good growth and we currently have over 500,000 test results based on blood tests in our database. We are the company that has done the most fatty acid analyses in the world.